Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hyperlipoproteinemias in psoriasis]

F Pfahl, J Rouffy, B Duperrat

    Annales De Dermatologie Et De Syphiligraphie
    |January 1, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.

    Oncogene·2016
    Same author

    A new posttranslational regulation of REDD1/DDIT4 through cleavage by caspase 3 modifies its cellular function.

    Cell death & disease·2014
    Same author

    SYK regulates mTOR signaling in AML.

    Leukemia·2013
    Same author

    Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death.

    Cell death and differentiation·2012
    Same author

    The caspase 6 derived N-terminal fragment of DJ-1 promotes apoptosis via increased ROS production.

    Cell death and differentiation·2012
    Same author

    The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia.

    Leukemia·2011
    Same journal

    Clinical research on psoriasis therapy.

    Annales de dermatologie et de syphiligraphie·2010
    Same journal

    Sulfamido-resistant gonococcal disease; Septicemia cured by penicillin.

    Annales de dermatologie et de syphiligraphie·2010
    Same journal

    Pruritic dermatosis in glass wool.

    Annales de dermatologie et de syphiligraphie·2010
    Same journal

    Ring of apparent preputial sclerosis in a circumcised ritual, in reality lymphangiomatous cystic dilation on scar.

    Annales de dermatologie et de syphiligraphie·2010
    Same journal

    Association of lupus erythematosus and psoriasis in a tuberculous impregnated.

    Annales de dermatologie et de syphiligraphie·2010
    Same journal

    Pruritus scrotal ferox with mutilating scratching lesions.

    Annales de dermatologie et de syphiligraphie·2010
    See all related articles

    Psoriasis is strongly linked to type IV hyperlipoproteinaemia, a genetic condition causing high triglyceride levels. This finding suggests psoriasis may be a metabolic disease, potentially connected to glucose metabolism issues.

    Area of Science:

    • Dermatology
    • Metabolic Medicine
    • Genetics

    Context:

    • Psoriasis, a chronic inflammatory skin condition, is frequently associated with metabolic disturbances.
    • Type IV hyperlipoproteinaemia (endogenous hypertriglyceridaemia) is identified as a characteristic lipid profile in psoriatic patients.

    Purpose:

    • To investigate the prevalence of type IV hyperlipoproteinaemia in patients with psoriasis.
    • To explore the potential link between psoriasis and metabolic diseases, specifically concerning glucose metabolism.

    Summary:

    • Type IV hyperlipoproteinaemia was observed in 39% of psoriasis patients, significantly higher than in controls (18%).
    • The condition appears to be primarily genetic, with environmental factors playing a minimal role.
    • This association supports classifying psoriasis within metabolic diseases, given the high prevalence (80%) of pre-diabetic states in type IV hyperlipoproteinaemia.

    Related Experiment Videos

    Impact:

    • Highlights a significant metabolic comorbidity in psoriasis patients.
    • Suggests a need for screening psoriatic individuals for hypertriglyceridaemia and pre-diabetic conditions.
    • Advances understanding of psoriasis as a systemic metabolic disorder, not solely a skin condition.